Takeda Pharmaceutical Company

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market

Retrieved on: 
Wednesday, December 4, 2019
Oncology, Health, FDA, Hospitals, General Health, Pharmaceutical, Drugs, Orphan drugs, Takeda Pharmaceutical Company, Clinical medicine, Health, Bortezomib, Janssen Pharmaceutica, Pyrazines, Multiple myeloma, Carfilzomib

This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio of products in the Hospital segment.

Key Points: 
  • This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio of products in the Hospital segment.
  • What Important Information Should I Know About Bortezomib for Injection, 3.5 mg/Vial?
  • Bortezomib for injection retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with bortezomib and who have relapsed at least six months after completing prior bortezomib treatment.
  • Treatment may be started at the last tolerated dose
    Who Should Not Use Bortezomib for Injection, 3.5 mg/Vial?

Metacrine to Present at Jefferies 2019 London Healthcare Conference

Retrieved on: 
Monday, November 18, 2019
Intercept Pharmaceuticals, Industries, Takeda Pharmaceutical Company

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 7:40 a.m.

Key Points: 
  • SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 7:40 a.m.
  • Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases.
  • The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases.
  • Privately held Metacrine is headquartered in San Diego, California.

Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting

Retrieved on: 
Thursday, November 14, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, RTT, Cancer, Neoplasms, Sarcoma, Clinical medicine, Ewing's sarcoma, FUS, Oncogenes, Takeda Pharmaceutical Company, ERG, TK216, the Study, Oncternal Therapeutics

Study TK216-01, Oncternals ongoing Phase 1 study of TK216 in patients with relapsed or refractory Ewing sarcoma, is a first-in-human, multicenter clinical trial.

Key Points: 
  • Study TK216-01, Oncternals ongoing Phase 1 study of TK216 in patients with relapsed or refractory Ewing sarcoma, is a first-in-human, multicenter clinical trial.
  • Patients entering the trial had previously been treated with a median of four, and up to nine prior lines of systemic therapy.
  • TK216 has been generally well tolerated in this trial, with common side effects including myelosuppression, fatigue, nausea and alopecia.
  • Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in most cases of Ewing sarcoma.

Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery® Platform

Retrieved on: 
Wednesday, November 13, 2019
Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Colitis, Takeda Pharmaceutical Company, Ulcerative colitis, Inflammatory bowel disease, Takeda

Finch Therapeutics Group, Inc. (Finch) and Takeda Pharmaceutical Company Limited (Takeda; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finchs Human-First Discovery platform.

Key Points: 
  • Finch Therapeutics Group, Inc. (Finch) and Takeda Pharmaceutical Company Limited (Takeda; TSE:4502/NYSE:TAK) announced today the expansion of their collaboration to develop microbiome-based therapeutics using Finchs Human-First Discovery platform.
  • Under the terms of the expanded agreement, Finch and Takeda will utilize Finchs platform to target Crohns disease, a form of inflammatory bowel disease.
  • In collaboration with Takeda, Finchs first RSM product, FIN-524, is advancing through pre-clinical development for the treatment of ulcerative colitis.
  • We are pleased to expand our collaboration with Takeda, said Mark Smith, PhD, CEO of Finch.

Poxel Announces Positive Update Following FDA Meeting for PXL065 for Treatment of NASH

Retrieved on: 
Friday, November 8, 2019
FDA, Health, Diabetes, Clinical trials, Pharmaceutical, Biotechnology, CYP17A1 inhibitors, Pyridines, Thiazolidinediones, Pioglitazone, RTT, Takeda Pharmaceutical Company, Thiazolidinedione, Chemical substances, Chemistry

PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, is a mitochondrial pyruvate carrier (MPC) inhibitor being developed for the treatment of NASH.

Key Points: 
  • PXL065, the deuterium-stabilized R-stereoisomer of pioglitazone, is a mitochondrial pyruvate carrier (MPC) inhibitor being developed for the treatment of NASH.
  • We plan to initiate a Phase 2 trial for PXL065 for the treatment of NASH during the second quarter of 2020 in biopsy-proven NASH patients.
  • Based upon preclinical and Phase 1 results to date, Poxel believes that PXL065 may have a better therapeutic profile than pioglitazone for NASH.
  • PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH.

Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting® 2019

Retrieved on: 
Thursday, November 7, 2019
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical trials, Pioglitazone, Pyridines, RTT, Takeda Pharmaceutical Company, Thiazolidinediones, Thiazolidinedione, MPC, Chemical substances

ePoster stations will be available throughout the meeting to provide continuous viewing access during and after the meeting in LiverLearning.

Key Points: 
  • ePoster stations will be available throughout the meeting to provide continuous viewing access during and after the meeting in LiverLearning.
  • In in vitro studies, PXL065 has been shown to target mitochondrial pyruvate carrier (MPC) as an inhibitor.
  • Based upon preclinical and Phase 1 results to date, Poxel believes that PXL065 may have a better therapeutic profile than pioglitazone for NASH.
  • PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH.

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Retrieved on: 
Thursday, November 7, 2019
Oncology, Health, Stem cells, Clinical trials, Pharmaceutical, Biotechnology, Orphan drugs, Takeda Pharmaceutical Company, Multiple myeloma, RTT, Boronic acids, Ixazomib, Clinical medicine, Medicine, Health, Plasma cell dyscrasias, Lenalidomide, the TOURMALINE-MM4 Trial, Multiple Myeloma, NINLAROTM

The trial evaluated the effect of single-agent oral NINLARO (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation.

Key Points: 
  • The trial evaluated the effect of single-agent oral NINLARO (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation.
  • We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients.
  • The typical multiple myeloma disease course includes periods of symptomatic myeloma followed by periods of remission.
  • Nearly 230,000 people around the world live with multiple myeloma, with approximately 114,000 new cases diagnosed globally each year.

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the ASH Annual Meeting

Retrieved on: 
Thursday, November 7, 2019
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Cancer treatments, Medical specialties, Medicine, Monoclonal antibodies, Takeda Pharmaceutical Company, Seattle Genetics, Antibody-drug conjugates, Brentuximab vedotin, CD30, Immunology, Antibody-drug conjugate, Monomethyl auristatin E

ADCETRIS is being evaluated globally as the foundation of care for CD30-expressing lymphomas in more than 70 corporate- and investigator-sponsored clinical trials.

Key Points: 
  • ADCETRIS is being evaluated globally as the foundation of care for CD30-expressing lymphomas in more than 70 corporate- and investigator-sponsored clinical trials.
  • At this years ASH meeting, ADCETRIS will be featured in 15 data presentations, including updated analyses from ECHELON-1 and ECHELON-2 phase 3 frontline trials, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics.
  • We continue to invest in our ADCETRIS clinical development program with the goal of improving outcomes for patients.
  • ADCETRIS (brentuximab vedotin) utilizes the companys industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas.

Takeda to Highlight Expanded Portfolio of Products Across Oncology and Hematology at 61st American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Organ systems, Medicine, Clinical medicine, Pain, Brentuximab vedotin, Takeda Pharmaceutical Company, Peripheral neuropathy, Neurological disorders, Hypoesthesia, Neuropathic pain, Dysesthesia, Paresthesia, ICLUSIG® (ponatinib) tablets, NINLARO™

Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.

Key Points: 
  • Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.
  • Available data indicate that MMAE clearance might be affected by severe renal impairment, hepatic impairment, and by low serum albumin concentrations.
  • Patients who are receiving a strong CYP3A4 and P-gp inhibitor, concomitantly with ADCETRIS may have an increased risk of neutropenia.
  • In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.

Takeda Unveils New Dengue Vaccine Manufacturing Plant in Germany

Retrieved on: 
Tuesday, November 5, 2019
Infectious diseases, Biotechnology, Pharmaceutical, Health, Health sciences, Health, Vaccines, Pharmaceutical sciences, Dengue fever, Dengue vaccine, Virology, Takeda Pharmaceutical Company, Vaccine, Pharmaceutical industry, Takeda

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced the opening of its new manufacturing plant in Singen, Germany, for its dengue vaccine candidate, TAK-003.
  • The Singen vaccine plant will be utilized for formulation, fill, finish and secondary packaging of the dengue vaccine candidate starting with the packaging line.
  • Takeda invested more than 130 million Euro and will employ up to 200 employees in the vaccine plant.
  • View the full release here: https://www.businesswire.com/news/home/20191105005718/en/
    Takeda senior leaders are joined by honored guests and employees at the grand opening of Takedas dengue vaccine manufacturing plant in Singen, Germany.